Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.

The Journal of infectious diseases - 1 Apr 2005

Lalezari Jacob P, Bellos Nicholaos C, Sathasivam Kunthavi, Richmond Gary J, Cohen Calvin J, Myers Robert A, Henry David H, Raskino Claire, Melby Tom, Murchison Hugh, Zhang Ying, Spence Rebecca, Greenberg Michael L, Demasi Ralph A, Miralles G Diego

Abstract excerpt

BACKGROUND: T-1249 is a 39-amino acid synthetic peptide fusion inhibitor (FI) shown to preserve antiretroviral activity in vitro against human immunodeficiency virus (HIV) isolates that have decreased susceptibility to enfuvirtide (ENF). METHODS: A 10-day phase 1/2 study of the safety and antiret...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to Enfuvirtide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Envelope Protein gp41

Share to HIV Fusion Inhibitors

Share to HIV Infections

Share to Peptide Fragments

Share to Treatment Failure

Source

Identifiers

PMID: 15747252
DOI: 10.1086/427993

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-15747252-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.PMID 15747252Read ↗

SC29EK, a Peptide Fusion Inhibitor with Enhanced α-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to EnfuvirtideSemantic proximity Read ↗

Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.Semantic proximity Read ↗

Enfuvirtide: the first HIV fusion inhibitorSemantic proximity Read ↗

Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations.Semantic proximity Read ↗

Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strainsSemantic proximity Read ↗

Selection of T1249-resistant human immunodeficiency virus type 1 variants.Semantic proximity Read ↗

A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.Semantic proximity Read ↗

Resistance to enfuvirtide, the first HIV fusion inhibitor.Semantic proximity Read ↗

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.Semantic proximity Read ↗

In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.Semantic proximity Read ↗

Research strategies of the N-peptide fusion inhibitor: a promising direction for discovering novel antiviralsSemantic proximity Read ↗

Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.